Compare BNZI & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BNZI | BRTX |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.7M |
| IPO Year | N/A | N/A |
| Metric | BNZI | BRTX |
|---|---|---|
| Price | $1.23 | $1.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $30.00 | N/A |
| AVG Volume (30 Days) | ★ 537.6K | 80.3K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,650,176.00 | $383,400.00 |
| Revenue This Year | $223.24 | $112.14 |
| Revenue Next Year | $31.42 | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 147.06 | 1.70 |
| 52 Week Low | $1.09 | $0.98 |
| 52 Week High | $27.00 | $2.55 |
| Indicator | BNZI | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.37 | 40.24 |
| Support Level | $1.14 | $1.06 |
| Resistance Level | $1.40 | $1.17 |
| Average True Range (ATR) | 0.15 | 0.11 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 31.83 | 27.80 |
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.